DAXOR CORP (DXR) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated July 11, 2023, reports on the results of Daxor Corporation's Annual Meeting of Shareholders held on that date. Daxor is a medical instrumentation and biotechnology company focused on blood volume measurement, primarily marketing the FDA-cleared BVA-100 Blood Volume Analyzer.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and shareholder voting. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
The primary material event reported is the election of directors and the ratification of the independent auditor. All seven director nominees were elected with significant majorities. The ratification of Steven Zelin & Associates, CPA, LLC as the independent registered public accounting firm was approved.
| Director Nominee | For Votes | Withheld Votes | Broker Non-votes |
|---|---|---|---|
| James Lombard | 3,498,907 | 87,254 | 0 |
| Henry D. Cremisi, MD | 3,500,783 | 85,378 | 0 |
| Edward Feuer | 3,500,783 | 85,378 | 0 |
| Joy Goudie, Esq. | 3,500,783 | 85,378 | 0 |
| Michael Feldschuh | 3,505,372 | 80,789 | 0 |
| Jonathan Feldschuh | 3,485,491 | 100,670 | 0 |
| Caleb DesRosiers, Esq. | 3,508,783 | 77,378 | 0 |
Other Matters:
- Ratification of Auditor: For: 3,568,964; Against: 16,671; Abstain: 526; Broker Non-votes: 0.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the impact of hiring sales staff and expanding distribution channels. Management notes that actual results may differ due to risks associated with post-market clinical data, product development, market acceptance, competition, intellectual property, and FDA regulatory actions. No specific financial guidance or outlook was provided in this document.
Investor Verification Checklist
- Verify the terms of office for the newly elected directors (expiring at the 2024 annual meeting).
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.
- Monitor future filings for updates on the commercialization of the BVA-100 and the expansion of distribution channels mentioned in the forward-looking statements.
- Confirm the independence and qualifications of the newly ratified auditor, Steven Zelin & Associates, CPA, LLC.